[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Antipyrine.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Orciprenaline.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Orciprenaline is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Mercaptopurine.]
[R03CC03, terbutaline, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Terbutaline.]
[N05AE05, lurasidone, The risk or severity of hypertension can be increased when Orciprenaline is combined with Lurasidone.]
[A04AD10, dronabinol, The risk or severity of Tachycardia can be increased when Dronabinol is combined with Orciprenaline.]
[R03DA07, theobromine, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Theobromine.]
[R03DA04, theophylline, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Theophylline.]
[N05AB08, thioproperazine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Thioproperazine.]
[N05AC02, thioridazine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Thioridazine.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Orciprenaline is combined with Moxisylyte.]
[V04CJ01, thyrotropin, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Thyrotropin.]
[V04CJ02, thyrotropin-releasing hormone, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Protirelin.]
[S01ED01, timolol, Timolol may decrease the bronchodilatory activities of Orciprenaline.]
[M02AX02, tolazoline, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Tolazoline.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Orciprenaline.]
[N02AX02, tramadol, The risk or severity of Tachycardia can be increased when Tramadol is combined with Orciprenaline.]
[N06AF04, tranylcypromine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Orciprenaline.]
[N06AX05, trazodone, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Trazodone.]
[S01BA05, triamcinolone, The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Orciprenaline.]
[C03AA06, trichlormethiazide, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Trichlormethiazide.]
[A03AB12, mepenzolate, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Mepenzolate.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Trifluoperazine.]
[N05AA05, triflupromazine, The risk or severity of Tachycardia can be increased when Triflupromazine is combined with Orciprenaline.]
[D07AC02, fluclorolone, The risk or severity of hypokalemia can be increased when Fluclorolone is combined with Orciprenaline.]
[N04AA01, trihexyphenidyl, The risk or severity of Tachycardia can be increased when Trihexyphenidyl is combined with Orciprenaline.]
[R03BA07, mometasone, The risk or severity of hypokalemia can be increased when Mometasone is combined with Orciprenaline.]
[A03AA05, trimebutine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Trimebutine.]
[C02BA01, trimethaphan, Orciprenaline may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Trimipramine.]
[A03BB01, butylscopolamine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of hypertension can be increased when Orciprenaline is combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, Orciprenaline may decrease the antihypertensive activities of Azilsartan medoxomil.]
[R03AC18, indacaterol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Indacaterol.]
[C08DA01, verapamil, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Verapamil.]
[C04AX07, vincamine, Orciprenaline may decrease the antihypertensive activities of Vincamine.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Orciprenaline is combined with Xenon.]
[C03BA10, xipamide, Orciprenaline may decrease the antihypertensive activities of Xipamide.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Zuclopenthixol.]
[N05AE04, ziprasidone, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Orciprenaline is combined with Acetylsalicylic acid.]
[G04BD07, tolterodine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Tolterodine.]
[C07AB03, atenolol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Atenolol.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Atropine is combined with Orciprenaline.]
[H02AB11, prednylidene, The risk or severity of hypokalemia can be increased when Prednylidene is combined with Orciprenaline.]
[G04BD12, mirabegron, The risk or severity of hypertension can be increased when Orciprenaline is combined with Mirabegron.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Octopamine.]
[H02AA01, aldosterone, The risk or severity of hypokalemia can be increased when Aldosterone is combined with Orciprenaline.]
[N04BD02, rasagiline, The risk or severity of hypertension can be increased when Orciprenaline is combined with Rasagiline.]
[C08CA13, lercanidipine, Orciprenaline may decrease the antihypertensive activities of Lercanidipine.]
[N02CC03, zolmitriptan, The risk or severity of hypertension can be increased when Zolmitriptan is combined with Orciprenaline.]
[R06AC06, thonzylamine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Thonzylamine.]
[G04BD10, darifenacin, The risk or severity of Tachycardia can be increased when Darifenacin is combined with Orciprenaline.]
[N01AA01, ethyl ether, The risk or severity of hypertension can be increased when Orciprenaline is combined with Diethyl ether.]
[C03AA01, bendroflumethiazide, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Bendroflumethiazide.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Orciprenaline is combined with Benorilate.]
[H03AA04, tiratricol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Tiratricol.]
[M01AH01, celecoxib, The risk or severity of hypertension can be increased when Celecoxib is combined with Orciprenaline.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Orciprenaline is combined with Naratriptan.]
[N04AC01, benztropine, The risk or severity of Tachycardia can be increased when Benzatropine is combined with Orciprenaline.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Benzydamine.]
[H05AA03, parathyroid hormone, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Parathyroid hormone.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the tachycardic activities of Orciprenaline.]
[C08EA02, bepridil, Orciprenaline may decrease the antihypertensive activities of Bepridil.]
[C02KX05, riociguat, Orciprenaline may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Orciprenaline may decrease the antihypertensive activities of Macitentan.]
[N06AX26, vortioxetine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Vortioxetine.]
[C01CA27, droxidopa, The therapeutic efficacy of Orciprenaline can be increased when used in combination with Droxidopa.]
[C07AB04, acebutolol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Acebutolol.]
[N07CA01, betahistine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Betahistine.]
[S03BA03, betamethasone, The risk or severity of hypokalemia can be increased when Betamethasone is combined with Orciprenaline.]
[S01ED02, betaxolol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Betaxolol.]
[C02CC01, bethanidine, Orciprenaline may decrease the antihypertensive activities of Bethanidine.]
[A03BA03, hyoscyamine, The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Orciprenaline.]
[R03AC19, olodaterol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Olodaterol.]
[D11AA01, glycopyrronium, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Glycopyrronium.]
[N05AA04, acepromazine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Acepromazine.]
[V04CX03, methacholine, Orciprenaline may decrease effectiveness of Methacholine as a diagnostic agent.]
[N04AA02, biperiden, The risk or severity of Tachycardia can be increased when Biperiden is combined with Orciprenaline.]
[N06AX11, mirtazapine, The risk or severity of hypertension can be increased when Mirtazapine is combined with Orciprenaline.]
[A03AA09, difemerine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Difemerine.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of hypertension can be increased when Orciprenaline is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Orciprenaline is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Orciprenaline is combined with Acemetacin.]
[B01AC27, selexipag, Orciprenaline may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Alfuzosin.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Orciprenaline is combined with Alminoprofen.]
[N04BC01, bromocriptine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[R06AB01, brompheniramine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Brompheniramine.]
[N06AA19, amineptin, The risk or severity of hypertension can be increased when Amineptine is combined with Orciprenaline.]
[C08CA01, amlodipine, Orciprenaline may decrease the antihypertensive activities of Amlodipine.]
[C03CA02, bumetanide, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Bumetanide.]
[C07AA19, bupranolol, Bupranolol may decrease the bronchodilatory activities of Orciprenaline.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Buspirone is combined with Orciprenaline.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Orciprenaline is combined with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Bambuterol.]
[R03DA08, bamifylline, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Bamifylline.]
[N06BC01, caffeine, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Caffeine.]
[C09AA07, benazepril, Orciprenaline may decrease the antihypertensive activities of Benazepril.]
[J01XX08, linezolid, The risk or severity of hypertension can be increased when Linezolid is combined with Orciprenaline.]
[H03BA03, benzylthiouracil, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Benzylthiouracil.]
[H05AA04, abaloparatide, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Abaloparatide.]
[N04BD03, safinamide, The risk or severity of hypertension can be increased when Orciprenaline is combined with Safinamide.]
[C07AB07, bisoprolol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Bitolterol.]
[C07AA17, bopindolol, Bopindolol may decrease the bronchodilatory activities of Orciprenaline.]
[N04AA11, bornaprine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Bornaprine.]
[R03BA02, budesonide, The risk or severity of hypokalemia can be increased when Budesonide is combined with Orciprenaline.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Orciprenaline is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Orciprenaline is combined with Bumadizone.]
[N06AA15, butriptyline, The risk or severity of hypertension can be increased when Butriptyline is combined with Orciprenaline.]
[C09AA01, captopril, Orciprenaline may decrease the antihypertensive activities of Captopril.]
[A03AA03, camylofine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Camylofin.]
[H03BB01, carbimazole, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Carbimazole.]
[C07AG02, carvedilol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Cannabidiol.]
[C07AB08, celiprolol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Celiprolol.]
[R06AA06, chlorphenoxamine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Orciprenaline is combined with Lornoxicam.]
[R03DA02, oxtriphylline, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Oxtriphylline.]
[C09AA08, cilazapril, Orciprenaline may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Orciprenaline is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Orciprenaline.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Orciprenaline is combined with Siponimod.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Orciprenaline.]
[H02AB14, cloprednol, The risk or severity of hypokalemia can be increased when Cloprednol is combined with Orciprenaline.]
[C09CA06, candesartan, Orciprenaline may decrease the antihypertensive activities of Candesartan.]
[H02AB17, cortivazol, The risk or severity of hypokalemia can be increased when Cortivazol is combined with Orciprenaline.]
[C03BX03, cicletanine, Orciprenaline may decrease the antihypertensive activities of Cicletanine.]
[C03AA09, cyclothiazide, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Yohimbine.]
[H02AB13, deflazacort, The risk or severity of hypokalemia can be increased when Deflazacort is combined with Orciprenaline.]
[N02CC07, frovatriptan, The risk or severity of hypertension can be increased when Orciprenaline is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Orciprenaline is combined with Dutasteride.]
[N02CC06, eletriptan, The risk or severity of hypertension can be increased when Eletriptan is combined with Orciprenaline.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Orciprenaline.]
[C01BD07, dronedarone, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Dronedarone.]
[C02AA06, methoserpidine, Orciprenaline may decrease the antihypertensive activities of Methoserpidine.]
[A03AA08, dihexyverine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Dopexamine.]
[D07XB03, fluprednidene, The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Orciprenaline.]
[G04BD09, trospium, The risk or severity of Tachycardia can be increased when Trospium is combined with Orciprenaline.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Orciprenaline is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Orciprenaline is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Orciprenaline is combined with Dexketoprofen.]
[C08CA17, levamlodipine, Orciprenaline may decrease the antihypertensive activities of Levamlodipine.]
[C03AA04, chlorothiazide, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Chlorothiazide.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, Orciprenaline may decrease the antihypertensive activities of Chlorthalidone.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Orciprenaline is combined with Ethenzamide.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Orciprenaline.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Orciprenaline is combined with Etofenamate.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Orciprenaline is combined with Naxitamab.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Orciprenaline is combined with Fenbufen.]
[N06BA10, fenethylline, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Fenethylline.]
[C01CA19, fenoldopam, Orciprenaline may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Orciprenaline is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Orciprenaline is combined with Finasteride.]
[R03BA03, flunisolide, The risk or severity of hypokalemia can be increased when Flunisolide is combined with Orciprenaline.]
[S02BA08, fluocinolone acetonide, The risk or severity of hypokalemia can be increased when Fluocinolone acetonide is combined with Orciprenaline.]
[R03CC15, formoterol, Orciprenaline may increase the sympathomimetic activities of Formoterol.]
[N01AB05, trichloroethylene, The risk or severity of hypertension can be increased when Orciprenaline is combined with Trichloroethylene.]
[H04AA02, dasiglucagon, Orciprenaline may decrease the antihypertensive activities of Dasiglucagon.]
[G03GA06, follitropin beta, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Follitropin.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Orciprenaline.]
[R03CC13, clenbuterol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Clenbuterol.]
[N06AA04, clomipramine, The risk or severity of hypertension can be increased when Clomipramine is combined with Orciprenaline.]
[S01EA04, clonidine, Orciprenaline may decrease the antihypertensive activities of Clonidine.]
[N05AH02, clozapine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Clozapine.]
[S02DA02, cocaine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Cocaine.]
[C02KB01, metyrosine, Orciprenaline may decrease the antihypertensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Orciprenaline is combined with Proquazone.]
[A03AB10, hexocyclium, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The risk or severity of Tachycardia can be increased when Homatropine methylbromide is combined with Orciprenaline.]
[N01AB07, desflurane, The risk or severity of hypertension can be increased when Orciprenaline is combined with Desflurane.]
[C04AX28, ifenprodil, The risk or severity of hypertension can be increased when Orciprenaline is combined with Ifenprodil.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Orciprenaline is combined with Imidazole salicylate.]
[R03BA08, ciclesonide, The risk or severity of hypokalemia can be increased when Ciclesonide is combined with Orciprenaline.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Orciprenaline is combined with Indobufen.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Orciprenaline.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Orciprenaline is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of hypertension can be increased when Orciprenaline is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Orciprenaline is combined with Parecoxib.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Orciprenaline is combined with Kebuzone.]
[C08CA09, lacidipine, Orciprenaline may decrease the antihypertensive activities of Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of Tachycardia can be increased when Lamotrigine is combined with Orciprenaline.]
[S01BA03, cortisone, The risk or severity of hypokalemia can be increased when Cortisone is combined with Orciprenaline.]
[N07BC04, lofexidine, Orciprenaline may decrease the antihypertensive activities of Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Orciprenaline is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Orciprenaline is combined with Loxoprofen.]
[C09AA03, lisinopril, Orciprenaline may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, Orciprenaline may decrease the antihypertensive activities of Manidipine.]
[A03AA04, mebeverine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Mebeverine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Orciprenaline is combined with Mefenorex.]
[C07AA14, mepindolol, Mepindolol may decrease the bronchodilatory activities of Orciprenaline.]
[H02AB15, meprednisone, The risk or severity of hypokalemia can be increased when Meprednisone is combined with Orciprenaline.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Orciprenaline.]
[N04AA03, methixene, The risk or severity of Tachycardia can be increased when Metixene is combined with Orciprenaline.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Methoxyphenamine.]
[C03DA04, eplerenone, Orciprenaline may decrease the antihypertensive activities of Eplerenone.]
[C03AA07, cyclopenthiazide, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Cyclopenthiazide.]
[N06AX07, minaprine, The risk or severity of hypertension can be increased when Minaprine is combined with Orciprenaline.]
[S01XA18, cyclosporine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Orciprenaline.]
[N06AG02, moclobemide, The risk or severity of hypertension can be increased when Orciprenaline is combined with Moclobemide.]
[R06AX02, cyproheptadine, The risk or severity of Tachycardia can be increased when Cyproheptadine is combined with Orciprenaline.]
[C09AA13, moexipril, Orciprenaline may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Orciprenaline is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Orciprenaline is combined with Morniflumate.]
[C02AC05, moxonidine, Orciprenaline may decrease the antihypertensive activities of Moxonidine.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Orciprenaline is combined with Etoricoxib.]
[C02CC04, debrisoquin, Orciprenaline may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of Tachycardia can be increased when Nabilone is combined with Orciprenaline.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Orciprenaline.]
[C07AB12, nebivolol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Nebivolol.]
[N06AX06, nefazodone, Nefazodone may increase the tachycardic activities of Orciprenaline.]
[C01DX16, nicorandil, Orciprenaline may decrease the antihypertensive activities of Nicorandil.]
[C01CA23, theodrenaline, The therapeutic efficacy of Orciprenaline can be increased when used in combination with Theodrenaline.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Norfenefrine.]
[G04BD08, solifenacin, The risk or severity of hypertension can be increased when Orciprenaline is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Olsalazine.]
[N06AA01, desipramine, The risk or severity of hypertension can be increased when Desipramine is combined with Orciprenaline.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Orciprenaline.]
[D07XC02, desoximetasone, The risk or severity of hypokalemia can be increased when Desoximetasone is combined with Orciprenaline.]
[H02AA03, desoxycorticosterone, The risk or severity of hypokalemia can be increased when Desoxycortone is combined with Orciprenaline.]
[C09XA02, aliskiren, Orciprenaline may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Orciprenaline is combined with Oxaprozin.]
[S03BA01, dexamethasone, The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Orciprenaline.]
[N04AA08, dexetimide, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Dexetimide.]
[G04BD04, oxybutynin, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Oxybutynin.]
[A03AA01, oxyphencyclimine, The risk or severity of Tachycardia can be increased when Oxyphencyclimine is combined with Orciprenaline.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Orciprenaline.]
[H05AA02, teriparatide, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Teriparatide.]
[N06AB05, paroxetine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Orciprenaline.]
[C04AD01, pentifylline, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Pentifylline.]
[V03AH01, diazoxide, Orciprenaline may decrease the antihypertensive activities of Diazoxide.]
[N06AA08, dibenzepin, The risk or severity of hypertension can be increased when Dibenzepin is combined with Orciprenaline.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Diclofenac is combined with Orciprenaline.]
[A03AA07, dicyclomine, The risk or severity of Tachycardia can be increased when Dicyclomine is combined with Orciprenaline.]
[C02DG01, pinacidil, Orciprenaline may decrease the antihypertensive activities of Pinacidil.]
[A03AB14, pipenzolate, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Pipenzolate.]
[R03CC07, pirbuterol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Pirbuterol.]
[C03CA03, piretanide, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Piretanide.]
[A08AA03, diethylpropion, The risk or severity of hypertension can be increased when Orciprenaline is combined with Diethylpropion.]
[C08CA03, isradipine, Orciprenaline may decrease the antihypertensive activities of Isradipine.]
[D07XC04, diflucortolone, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Orciprenaline.]
[A03AB11, poldine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Orciprenaline is combined with Diflunisal.]
[C02DB01, dihydralazine, Orciprenaline may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[B01AC21, treprostinil, Orciprenaline may decrease the antihypertensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Potassium perchlorate.]
[C08DB01, diltiazem, Orciprenaline may decrease the antihypertensive activities of Diltiazem.]
[R06AB03, dimethindene, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Dimetindene.]
[R03CC08, procaterol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Procaterol.]
[N06BC02, propentofylline, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Propentofylline.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Orciprenaline is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Orciprenaline is combined with Proglumetacin.]
[R03DA03, proxyphylline, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Proxyphylline.]
[R06AA02, diphenhydramine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Diphenhydramine.]
[C09AA06, quinapril, Orciprenaline may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Orciprenaline is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of hypertension can be increased when Quinupramine is combined with Orciprenaline.]
[C09AA05, ramipril, Orciprenaline may decrease the antihypertensive activities of Ramipril.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Reproterol.]
[C01BA03, disopyramide, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Orciprenaline.]
[N05AX08, risperidone, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Risperidone.]
[G04BE08, tadalafil, Orciprenaline may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Orciprenaline.]
[C02KX02, ambrisentan, Orciprenaline may decrease the antihypertensive activities of Ambrisentan.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Orciprenaline is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Salmeterol.]
[H05BA01, salmon calcitonin, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Salmon calcitonin.]
[C01CA07, dobutamine, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Dobutamine.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of hypertension can be increased when Dosulepin is combined with Orciprenaline.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Orciprenaline.]
[N06AA12, doxepin, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Doxepin.]
[R06AA09, doxylamine, The risk or severity of Tachycardia can be increased when Doxylamine is combined with Orciprenaline.]
[N01AB08, sevoflurane, The risk or severity of hypertension can be increased when Orciprenaline is combined with Sevoflurane.]
[N05AD08, droperidol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Droperidol.]
[A08AA10, sibutramine, Sibutramine may increase the tachycardic activities of Orciprenaline.]
[C09AA11, spirapril, Orciprenaline may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Dyphylline.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Sumatriptan is combined with Orciprenaline.]
[C07AB13, talinolol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hypokalemia can be increased when Corticotropin is combined with Orciprenaline.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Orciprenaline.]
[G04CA03, terazosin, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Terazosin.]
[C07AA16, tertatolol, Tertatolol may decrease the bronchodilatory activities of Orciprenaline.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Orciprenaline is combined with Tetryzoline.]
[G04BD01, emepronium, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Emepronium.]
[N06AX14, tianeptine, The risk or severity of hypertension can be increased when Tianeptine is combined with Orciprenaline.]
[C09AA02, enalapril, Orciprenaline may decrease the antihypertensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Orciprenaline is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of hypertension can be increased when Orciprenaline is combined with Toloxatone.]
[N06BA09, atomoxetine, Atomoxetine may increase the tachycardic activities of Orciprenaline.]
[C03CA04, torsemide, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Orciprenaline is combined with Tramazoline.]
[C09AA10, trandolapril, Orciprenaline may decrease the antihypertensive activities of Trandolapril.]
[A03AB08, tridihexethyl, The risk or severity of Tachycardia can be increased when Tridihexethyl is combined with Orciprenaline.]
[H02CA01, trilostane, The risk or severity of hypokalemia can be increased when Trilostane is combined with Orciprenaline.]
[G03GA05, follitropin alfa, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Follitropin.]
[N04AA12, tropatepine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Tulobuterol.]
[C02CA06, urapidil, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Urapidil.]
[S01FB02, ephedrine, The therapeutic efficacy of Orciprenaline can be increased when used in combination with Ephedrine.]
[N06AX16, venlafaxine, Venlafaxine may increase the tachycardic activities of Orciprenaline.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Orciprenaline is combined with Xylometazoline.]
[S01EA01, epinephrine, The therapeutic efficacy of Orciprenaline can be increased when used in combination with Epinephrine.]
[C09AA15, zofenopril, Orciprenaline may decrease the antihypertensive activities of Zofenopril.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Orciprenaline is combined with Zomepirac.]
[C02AC02, guanfacine, Orciprenaline may decrease the antihypertensive activities of Guanfacine.]
[G02AB03, ergonovine, Ergometrine may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[N02CA02, ergotamine, Ergotamine may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[R03BA09, fluticasone furoate, The risk or severity of hypokalemia can be increased when Fluticasone furoate is combined with Orciprenaline.]
[R03BA05, fluticasone, The risk or severity of hypokalemia can be increased when Fluticasone is combined with Orciprenaline.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Gepefrine.]
[N04AA05, profenamine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Profenamine.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Orciprenaline.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Etomidate is combined with Orciprenaline.]
[C08CA02, felodipine, Orciprenaline may decrease the antihypertensive activities of Felodipine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Orciprenaline.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of hypertension can be increased when Fentanyl is combined with Orciprenaline.]
[R03CC02, albuterol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Salbutamol.]
[G04BD02, flavoxate, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Flavoxate.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Floctafenine.]
[H02AA02, fludrocortisone, The risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Orciprenaline.]
[D07XB01, flumethasone, The risk or severity of hypokalemia can be increased when Flumethasone is combined with Orciprenaline.]
[D07AC08, fluocinonide, The risk or severity of hypokalemia can be increased when Fluocinonide is combined with Orciprenaline.]
[N06AA14, melitracen, The risk or severity of hypertension can be increased when Melitracen is combined with Orciprenaline.]
[H02AB03, fluocortolone, The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Orciprenaline.]
[S01CB05, fluorometholone, The risk or severity of hypokalemia can be increased when Fluorometholone is combined with Orciprenaline.]
[N05AF01, flupenthixol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Flupentixol.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Orciprenaline.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Orciprenaline is combined with Adrafinil.]
[G01AX06, furazolidone, The risk or severity of hypertension can be increased when Furazolidone is combined with Orciprenaline.]
[C03CA01, furosemide, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Furosemide.]
[N04BC06, cabergoline, Cabergoline may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[C01CA21, cafedrine, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Cafedrine.]
[N01AH02, alfentanil, The risk or severity of hypertension can be increased when Alfentanil is combined with Orciprenaline.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Orciprenaline.]
[N05CM18, dexmedetomidine, The risk or severity of hypertension can be increased when Dexmedetomidine is combined with Orciprenaline.]
[C05AE01, nitroglycerin, Orciprenaline may decrease the antihypertensive activities of Nitroglycerin.]
[C02CA04, doxazosin, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Doxazosin.]
[H01AB01, thyrotropin alfa, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Thyrotropin alfa.]
[C07AB09, esmolol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Esmolol.]
[C09AA09, fosinopril, Orciprenaline may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Orciprenaline may decrease the antihypertensive activities of Guanethidine.]
[N01AB01, halothane, The risk or severity of hypertension can be increased when Orciprenaline is combined with Halothane.]
[N05AH04, quetiapine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Quetiapine.]
[C09CA01, losartan, Orciprenaline may decrease the antihypertensive activities of Losartan.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Orciprenaline.]
[R03CC05, hexoprenaline, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Hexoprenaline.]
[C08CA10, nilvadipine, Orciprenaline may decrease the antihypertensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Orciprenaline is combined with Nimesulide.]
[C09AA04, perindopril, Orciprenaline may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Orciprenaline may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Orciprenaline.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Orciprenaline.]
[C03AA02, hydroflumethiazide, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Hydroflumethiazide.]
[G04BD06, propiverine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Propiverine.]
[C02AC06, rilmenidine, Orciprenaline may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Orciprenaline is combined with Ibuprofen.]
[N01AH03, sufentanil, The risk or severity of hypertension can be increased when Sufentanil is combined with Orciprenaline.]
[N06AA02, imipramine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Imipramine.]
[R01AD07, tixocortol, The risk or severity of hypokalemia can be increased when Tixocortol is combined with Orciprenaline.]
[M03BX02, tizanidine, The risk or severity of Tachycardia can be increased when Tizanidine is combined with Orciprenaline.]
[C03BA11, indapamide, Orciprenaline may decrease the antihypertensive activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Orciprenaline.]
[C02CA02, indoramin, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Indoramin.]
[N06AX17, milnacipran, Milnacipran may increase the tachycardic activities of Orciprenaline.]
[A03AA30, piperidolate, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Piperidolate.]
[R06AE01, buclizine, The risk or severity of Tachycardia can be increased when Buclizine is combined with Orciprenaline.]
[G02CX01, atosiban, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Atosiban.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Anagrelide is combined with Orciprenaline.]
[C07AA01, alprenolol, Alprenolol may decrease the bronchodilatory activities of Orciprenaline.]
[C03BA02, quinethazone, Orciprenaline may increase the hypokalemic activities of Quinethazone.]
[N06AA13, iprindole, The risk or severity of hypertension can be increased when Iprindole is combined with Orciprenaline.]
[N06AF05, iproniazid, The risk or severity of hypertension can be increased when Orciprenaline is combined with Iproniazid.]
[N06AF01, isocarboxazid, The risk or severity of hypertension can be increased when Orciprenaline is combined with Isocarboxazid.]
[R03CC06, isoetharine, The risk or severity of adverse effects can be increased when Isoetharine is combined with Orciprenaline.]
[C09AA16, imidapril, Orciprenaline may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of hypertension can be increased when Isoflurane is combined with Orciprenaline.]
[R03CB01, isoproterenol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Isoprenaline.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Isoxsuprine.]
[N01AX03, ketamine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Ketamine.]
[C02KD01, ketanserin, Orciprenaline may decrease the antihypertensive activities of Ketanserin.]
[N05AH03, olanzapine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Orciprenaline is combined with Ketoprofen.]
[C01CA22, arbutamine, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Arbutamine.]
[N04BC09, rotigotine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Orciprenaline is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Labetalol.]
[C02AA05, deserpidine, Orciprenaline may decrease the antihypertensive activities of Deserpidine.]
[C03CC01, ethacrynic acid, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Etacrynic acid.]
[N02CA07, lisuride, Lisuride may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[N06AA07, lofepramine, The risk or severity of hypertension can be increased when Lofepramine is combined with Orciprenaline.]
[N05AH01, loxapine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Loxapine.]
[N06AA21, maprotiline, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Orciprenaline.]
[C02BB01, mecamylamine, Orciprenaline may decrease the antihypertensive activities of Mecamylamine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Orciprenaline is combined with Meclofenamic acid.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Mephentermine.]
[N05AX13, paliperidone, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Orciprenaline.]
[N06BA03, methamphetamine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Metamfetamine.]
[A03AB07, methantheline, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Methantheline.]
[G02CB05, metergoline, Metergoline may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Methimazole.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Orciprenaline.]
[N02BG09, methoxyflurane, The risk or severity of hypertension can be increased when Orciprenaline is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Methyclothiazide.]
[C02AB01, methyldopa, Orciprenaline may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, The risk or severity of hypertension can be increased when Orciprenaline is combined with Methylene blue.]
[G02AB01, methylergonovine, Methylergometrine may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[R03DA05, aminophylline, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Aminophylline.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Orciprenaline.]
[H02AB04, methylprednisolone, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Orciprenaline.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Orciprenaline.]
[N02CA04, methysergide, Methysergide may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[C03BA08, metolazone, Orciprenaline may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Metoprolol.]
[N06AX03, mianserin, The risk or severity of hypertension can be increased when Orciprenaline is combined with Mianserin.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Aminophenazone.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Orciprenaline.]
[C09CA03, valsartan, Orciprenaline may decrease the antihypertensive activities of Valsartan.]
[D11AX01, minoxidil, Orciprenaline may decrease the antihypertensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Lisdexamfetamine.]
[N06AA09, amitriptyline, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Amitriptyline.]
[G04CA04, silodosin, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Silodosin.]
[R03BB01, ipratropium bromide, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Orciprenaline.]
[N06AA17, amoxapine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Amoxapine.]
[C07AA12, nadolol, Nadolol may decrease the bronchodilatory activities of Orciprenaline.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Orciprenaline is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Orciprenaline.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Naproxen is combined with Orciprenaline.]
[N06AX21, duloxetine, Duloxetine may increase the tachycardic activities of Orciprenaline.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Orciprenaline is combined with Remifentanil.]
[N05AX14, iloperidone, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Iloperidone.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the tachycardic activities of Orciprenaline.]
[C09CA07, telmisartan, Orciprenaline may decrease the antihypertensive activities of Telmisartan.]
[N06AF02, nialamide, The risk or severity of hypertension can be increased when Orciprenaline is combined with Nialamide.]
[C08CA04, nicardipine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Nicardipine.]
[C04AE02, nicergoline, Nicergoline may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Orciprenaline.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Orciprenaline is combined with Niflumic acid.]
[C08CA06, nimodipine, Orciprenaline may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Orciprenaline may decrease the antihypertensive activities of Nisoldipine.]
[C08CA08, nitrendipine, Orciprenaline may decrease the antihypertensive activities of Nitrendipine.]
[C02DD01, nitroprusside, Orciprenaline may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of hypertension can be increased when Orciprenaline is combined with Nitrous oxide.]
[C01CA03, norepinephrine, The therapeutic efficacy of Orciprenaline can be increased when used in combination with Norepinephrine.]
[C02KX01, bosentan, Orciprenaline may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Nortriptyline.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Orciprenaline is combined with Nylidrin.]
[N06AA05, opipramol, The risk or severity of hypertension can be increased when Opipramol is combined with Orciprenaline.]
[G04CA02, tamsulosin, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Tamsulosin.]
[C07AA02, oxprenolol, Oxprenolol may decrease the bronchodilatory activities of Orciprenaline.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Orciprenaline is combined with Oxymetazoline.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Orciprenaline is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Orciprenaline.]
[N05AH05, asenapine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Asenapine.]
[M03AC01, pancuronium, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Pancuronium.]
[H02AB05, paramethasone, The risk or severity of hypokalemia can be increased when Paramethasone is combined with Orciprenaline.]
[C02KC01, pargyline, Orciprenaline may decrease the antihypertensive activities of Pargyline.]
[G04BD11, fesoterodine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Fesoterodine.]
[C07AA23, penbutolol, Penbutolol may decrease the bronchodilatory activities of Orciprenaline.]
[C04AD03, pentoxifylline, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Pentoxifylline.]
[N04BC02, pergolide, Pergolide may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[N06AF03, phenelzine, The risk or severity of hypertension can be increased when Phenelzine is combined with Orciprenaline.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Phenoxybenzamine.]
[A08AA01, phentermine, The risk or severity of hypertension can be increased when Phentermine is combined with Orciprenaline.]
[V03AB36, phentolamine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Orciprenaline.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Orciprenaline.]
[R01BA01, phenylpropanolamine, The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Orciprenaline.]
[C08CX01, mibefradil, Orciprenaline may decrease the antihypertensive activities of Mibefradil.]
[C07AA03, pindolol, Pindolol may decrease the bronchodilatory activities of Orciprenaline.]
[C09CA02, eprosartan, Orciprenaline may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, The risk or severity of Tachycardia can be increased when Pirenzepine is combined with Orciprenaline.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Orciprenaline.]
[N02CX01, pizotyline, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Pizotifen.]
[C09CA04, irbesartan, Orciprenaline may decrease the antihypertensive activities of Irbesartan.]
[C03AA05, polythiazide, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Polythiazide.]
[V03AB21, potassium iodide, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Potassium Iodide.]
[C07AB01, practolol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Practolol.]
[C02CA01, prazosin, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Prazosin.]
[S03BA02, prednisolone, The risk or severity of hypokalemia can be increased when Prednisolone is combined with Orciprenaline.]
[H02AB07, prednisone, The risk or severity of hypokalemia can be increased when Prednisone is combined with Orciprenaline.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Orciprenaline.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Orciprenaline.]
[N04AA04, procyclidine, The risk or severity of Tachycardia can be increased when Procyclidine is combined with Orciprenaline.]
[N05AA03, promazine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Promethazine.]
[C01BC03, propafenone, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Propafenone.]
[A03AB05, propantheline, The risk or severity of Tachycardia can be increased when Propantheline is combined with Orciprenaline.]
[N05AC01, periciazine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Periciazine.]
[N05CM06, propiomazine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Propiomazine.]
[N01AX10, propofol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Propofol.]
[C07AA05, propranolol, Propranolol may decrease the bronchodilatory activities of Orciprenaline.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Propylthiouracil.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Orciprenaline is combined with Rizatriptan.]
[B01AC09, epoprostenol, Orciprenaline may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of hypertension can be increased when Protriptyline is combined with Orciprenaline.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Orciprenaline is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Aripiprazole.]
[A03AB15, diphemanil, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Isopropamide.]
[S01FA03, methscopolamine, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Methscopolamine.]
[C01BA01, quinidine, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Quinidine.]
[C02AA01, rescinnamine, Orciprenaline may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, Orciprenaline may decrease the antihypertensive activities of Reserpine.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Ritodrine.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Orciprenaline is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Orciprenaline.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Orciprenaline is combined with Salicylic acid.]
[S01FA02, scopolamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Orciprenaline.]
[N04BD01, selegiline, The risk or severity of hypertension can be increased when Orciprenaline is combined with Selegiline.]
[C07AA07, sotalol, Sotalol may decrease the bronchodilatory activities of Orciprenaline.]
[C03DA01, spironolactone, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Spironolactone.]
